Polygraphic evaluation of ethchlorvynol (14 days)

Area of Science:

• Pharmacology
• Sleep Medicine
• Clinical Psychology

Background:

• Insomnia is a prevalent sleep disorder affecting millions.
• Hypnotic medications are frequently prescribed, necessitating efficacy and safety evaluations.
• Ethchlorvynol is a sedative-hypnotic agent with a history of use for insomnia.

Purpose of the Study:

• To evaluate the efficacy of ethchlorvynol in improving sleep in young insomniacs.
• To assess the impact of ethchlorvynol on mood and sleep architecture.
• To identify potential side effects associated with ethchlorvynol administration and withdrawal.

Main Methods:

• A 14-day administration of ethchlorvynol (500 mg) within a 22-day sleep laboratory protocol.
• Objective sleep monitoring and subjective mood assessments were conducted.
• Analysis included comparison of sleep parameters, mood, and sleep stages (REM, stage 1) during drug administration and withdrawal periods against baseline.

Main Results:

• While subjects reported increased sleep time with ethchlorvynol, this effect was not statistically significant.
• Ethchlorvynol administration and withdrawal were associated with mood impairment compared to baseline.
• Significant suppression of Stage REM and Stage 1 sleep was observed; Stage 1 sleep showed a withdrawal rebound.

Conclusions:

• Ethchlorvynol (500 mg) demonstrated limited efficacy in improving sleep for young insomniacs.
• The drug negatively affected mood and sleep architecture, with notable side effects reported.
• Findings suggest caution in the use of ethchlorvynol due to its adverse effects on mood and sleep patterns.